Logo

PharmaShots Weekly Snapshots (June 06– 10, 2022)

Share this

PharmaShots Weekly Snapshots (June 06– 10, 2022)

BeiGene’s Tislelizumab Receives NMPA’s Approval for the Treatment of Recurrent or Metastatic Nasopharyngeal Cancer

Published: June 10, 2022 | Tags: BeiGene, Tislelizumab, NMPA, Approval, Nasopharyngeal Cancer

Amarin’s Vazkepa (icosapent ethyl) Receives NICE Recommendation for the Treatment of Cardiovascular Disease

Published: June 10, 2022 | Tags: Amarin, Vazkepa, icosapent ethyl, NICE, Recommendation, Cardiovascular Disease

Everest Medicines’ Trodelvy (sacituzumab govitecan) Receives NMPA’s Approval as 2L Treatment of Metastatic Triple-Negative Breast Cancer

Published: June 10, 2022 | Tags: Everest Medicines, Trodelvy, sacituzumab govitecan, NMPA, Approval, Metastatic Triple-Negative Breast Cancer

AbbVie Presents Five-Year Follow-Up Analysis in P-III CLL14 Trial for Venclyxto/Venclexta to Treat Chronic Lymphocytic Leukemia at EHA 2022

Published: June 10, 2022 | Tags: AbbVie, P-III, CLL14 Trial, Venclyxto, Venclexta, Chronic Lymphocytic Leukemia, EHA, 2022

Adverum Reports Three-Year Results of ADVM-022 in (OPTIC) Study for the Treatment of Wet Age-Related Macular Degeneration

Published: June 10, 2022 | Tags: Adverum, ADVM-022, OPTIC Study, Wet, Age-Related Macular Degeneration

Olema Entered into an Exclusive Worldwide License Agreement with Aurigene to Develop and Commercialize Novel Cancer Therapies

Published: June 10, 2022 | Tags: Olema, Aurigene, Cancer, Palbociclib, OP-1250

STADA and Alvotech Launch AVT02 (biosimilar, adalimumab) for the Treatment of Inflammatory Conditions

Published: June 9, 2022 | Tags: STADA , Alvotech, AVT02, biosimilar, adalimumab, Inflammatory Conditions

Takeda Presents Results of TAK-003 in P-III (TIDES) Trial for the Prevention of Dengue at NECTM8 2022

Published: June 9, 2022 | Tags: Takeda, TAK-003, P-III, TIDES Trial, Dengue, NECTM8, 2022

Vertex’s Inaxaplin (VX-147) Receives the US FDA’s Breakthrough Therapy Designation & EMA’s PRIME Designation for APOL1-Mediated FSGS & AMKD

Published: June 9, 2022 | Tags: Vertex, Inaxaplin, VX-147, US, FDA, Breakthrough Therapy Designation, EMA, PRIME Designation, APOL1-Mediated, FSGS, AMKD

Abbott Reports Results of MitraClip & TriClip Device in Multiple Studies for the Treatment of Patients with Heart Failure

Published: June 9, 2022 | Tags: Abbott, MitraClip, TriClip Device, Heart Failure

Immunocore’s Kimmtrak (tebentafusp) Receives Approval for the Treatment of Unresectable Or Metastatic Uveal Melanoma in the UK, Australia, Canada

Published: June 9, 2022 | Tags: Immunocore, Kimmtrak, tebentafusp, Approval, Uveal Melanoma, UK, Australia, Canada

AstraZeneca Reports Results of Evusheld (tixagevimab and cilgavimab) in P-III (TACKLE) Trial for the Treatment of COVID-19

Published: June 9, 2022 | Tags: AstraZeneca, Evusheld, tixagevimab, cilgavimab, P-III, TACKLE Trial, COVID-19

Moderna Reports Results of Bivalent Booster mRNA -1273.214 in P-II/III Trial Demonstrated Superior Antibody Response Against Omicron

Published: June 8, 2022 | Tags: Moderna, Bivalent, Booster, mRNA -1273.214, P-II/III Trial, Omicron

Roche’s Lunsumio (mosunetuzumab) Receives EC’s Approval for the Treatment of Relapsed or Refractory Follicular Lymphoma

Published: June 8, 2022 | Tags: Roche, Lunsumio, mosunetuzumab, EC, Approval, Follicular Lymphoma

SeaStar Medical and LMF Published Results of Selective Cytopheretic Device in (Pilot SCD 005) Study for COVID-19 in SCCM 2022, Critical Care Explorations

Published: June 8, 2022 | Tags: SeaStar Medical, Selective Cytopheretic Device, Pilot SCD 005 Study, COVID-19, SCCM, 2022

Sanofi’s Dupixent (dupilumab) Receives the US FDA’s Approval for the Treatment of Atopic Dermatitis in Children Aged 6 months to 5 years

Published: June 8, 2022 | Tags: Sanofi, Dupixent, dupilumab, US, FDA, Approval, Atopic Dermatitis

Merck and Ridgeback Report Results of Lagevrio (molnupiravir) in P-III (MOVe-OUT) Trial for the Treatment of COVID-19

Published: June 8, 2022 | Tags: Merck, Ridgeback, Lagevrio, molnupiravir, P-III, MOVe-OUT Trial, COVID-19

Novartis Presents Results of Tafinlar (dabrafenib) + Mekinist (trametinib) in P-II/III (TADPOLE) Trial for BRAF V600 Low-Grade Gliomas at ASCO 2022

Published: June 8, 2022 | Tags: Novartis, Tafinlar, dabrafenib, Mekinist, trametinib, P-II/III, TADPOLE Trial, BRAF V600, Low-Grade Gliomas, ASCO, 2022

GSK’s Priorix Receives the US FDA’s Approval for the Prevention of Measles, Mumps and Rubella in Patients Aged ≥12 Months

Published: June 7, 2022 | Tags: GSK, Priorix, US, FDA, Approval, Measles, Mumps, Rubella

Eli Lilly Reports Results of Lebrikizumab in P-III (ADvocate 1 & 2) Trial for the Treatment of Atopic Dermatitis

Published: June 7, 2022 | Tags: Eli Lilly, Lebrikizumab, P-III, ADvocate 1, ADvocate 2 Trial, Atopic Dermatitis

Abbott Presents Results of Freestyle Libre 3 System for the Treatment of Type 1 or Type 2 Diabetes at ADA 2022

Published: June 7, 2022 | Tags: Abbott, Freestyle Libre 3 System, Type 1, Type 2 Diabetes, ADA, 2022

Amgen’s Riabni (biosimilar, rituximab) Receives the US FDA’s Approval for the Treatment of Rheumatoid Arthritis

Published: June 7, 2022 | Tags: Amgen’s Riabni, biosimilar, rituximab, US, FDA, Approval, Rheumatoid Arthritis

BMS Reports Three and Five-Year Data of Opdivo (nivolumab) + Yervoy (ipilimumab) in P-III (CheckMate -9LA) and (CheckMate -227) Trial for mNSCLC

Published: June 7, 2022 | Tags: BMS, Opdivo, nivolumab, Yervoy, ipilimumab, P-III, CheckMate -9LA, CheckMate -227 Trial, mNSCLC

Biogen Entered into a License and Collaboration Agreement with Alectos to Develop and Commercialize AL01811 for Parkinson’s Disease

Published: June 7, 2022 | Tags: Biogen, Alectos, AL01811, Parkinson’s Disease

Yumanity Signs a Purchase Agreement with Janssen for YTX-7739 & Reverse Merged with Kineta to Advance KVA12.1

Published: June 6, 2022 | Tags: Yumanity, Purchase Agreement, Janssen, YTX-7739, Kineta, KVA12.1

AstraZeneca Presents Results of Calquence (acalabrutinib) in P-III (ELEVATE-TN) Trial as 1L Treatment of Chronic Lymphocytic Leukaemia at ASCO 2022

Published: June 6, 2022 | Tags: AstraZeneca, Calquence, acalabrutinib, P-III, ELEVATE-TN Trial, Chronic Lymphocytic Leukaemia, ASCO, 2022

Insulet Presents Results of Omnipod 5 Automated Insulin Delivery System Demonstrated Improved Glycemic Outcomes in Children with Type 1 Diabetes at ADA 2022

Published: June 6, 2022 | Tags: Insulet, Omnipod 5 Automated Insulin Delivery System, Glycemic Outcomes, Type 1 Diabetes, ADA, 2022

Biogen and Bio-Thera Solutions Present Results of BIIB800 (biosimilar, tocilizumab) in P-III Trial for Rheumatoid Arthritis at EULAR 2022

Published: June 6, 2022 | Tags: Biogen, Bio-Thera Solutions, BIIB800, biosimilar, tocilizumab, P-III Trial, Rheumatoid Arthritis, EULAR, 2022

Merck Presents Results of Keytruda (pembrolizumab) in P-III (KEYNOTE-716) Trial for the Treatment of Resected Stage IIB or IIC Melanoma at ASCO 2022

Published: June 6, 2022 | Tags: Merck, Keytruda, pembrolizumab, P-III, KEYNOTE-716 Trial, Resected, Stage IIB, IIC, Melanoma, ASCO, 2022

Eli Lilly Publishes Results of Tirzepatide in P-III (SURMOUNT-1) Trial for the Treatment of Obesity or Overweight in the NEJM

Published: June 6, 2022 | Tags: Eli Lilly, Tirzepatide, P-III, SURMOUNT-1 Trial, Obesity, Overweight, NEJM

Related Post: PharmaShots Weekly Snapshots (May 30 – June 03, 2022)


Senior Editor

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions